Atossa Therapeutics, Inc.
ATOS
$2.40
-$0.12-4.57%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 33.54% | 31.49% | 18.15% | 9.92% | 2.78% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.88% | 41.14% | 34.47% | 11.42% | -1.90% |
| Operating Income | -30.88% | -41.14% | -34.47% | -11.42% | 1.90% |
| Income Before Tax | -31.31% | -42.88% | -36.33% | -12.15% | -10.84% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -31.31% | -42.88% | -36.33% | -12.15% | -10.84% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -31.31% | -42.88% | -36.33% | -12.15% | -10.84% |
| EBIT | -30.88% | -41.14% | -34.47% | -11.42% | 1.90% |
| EBITDA | -30.90% | -41.16% | -34.49% | -11.47% | 1.87% |
| EPS Basic | -28.91% | -40.24% | -32.76% | -9.38% | -8.85% |
| Normalized Basic EPS | -37.20% | -50.06% | -42.32% | -16.79% | -2.27% |
| EPS Diluted | -28.91% | -40.24% | -32.76% | -9.38% | -8.85% |
| Normalized Diluted EPS | -37.20% | -50.06% | -42.32% | -16.79% | -2.27% |
| Average Basic Shares Outstanding | 2.01% | 1.88% | 2.70% | 2.46% | 1.77% |
| Average Diluted Shares Outstanding | 2.01% | 1.88% | 2.70% | 2.46% | 1.77% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |